Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
17th Nov 2024 18:14
(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike targets within the Kursk region, the New York Times reported. Speculation may increase that permission from Britain, the US and France to do the same with Storm Shadow missiles could follow. Joe Biden's decision is said to have been triggered by the appearance of North Korean troops in the Kursk region. - The Sunday Telegraph
Read moreDirector dealings: AstraZeneca CEO ups stake
15th Nov 2024 16:11
(Sharecast News) - AstraZeneca revealed on Friday that chief executive officer Pascal Soriot had acquired 20,000 ordinary shares in the FTSE 100-listed drugmaker.
Read moreLondon close: Stocks end turbulent week in the red
15th Nov 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
Read moreLondon close: Stocks sink as UK jobless rate rises
12th Nov 2024 16:39
(Sharecast News) - London stocks fell sharply on Tuesday as investors digested recent UK employment data alongside broader market reactions to Donald Trump's US presidential victory last week.
Read moreAstraZeneca upgrades full-year guidance amid strong momentum
12th Nov 2024 07:17
(Sharecast News) - AstraZeneca upgraded its full-year revenue and earnings per share guidance on Tuesday, citing strong growth across key therapy areas and robust financial results for the first nine months of the year.
Read moreAstraZeneca "excited" by positive results in Tezspire clinical trial
8th Nov 2024 07:19
(Sharecast News) - AstraZeneca has announced positive high-level results from a phase III for its Texspire treatment for nasal polyps.
Read moreAstraZeneca says does not comment on media reports as shares slump
5th Nov 2024 17:18
(Sharecast News) - AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share price.
Read moreAstraZeneca China president under investigation
30th Oct 2024 13:37
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Leon Wang, the president of AstraZeneca China, was under investigation by Chinese authorities.
Read moreAstraZeneca's nerve damage treatment recommended for approval in EU
21st Oct 2024 07:10
(Sharecast News) - Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU.
Read moreHutchmed reports positive results from AstraZeneca lung cancer collaboration
16th Oct 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys', or savolitinib, in treating patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), who had high levels of MET overexpression or amplification and whose disease progressed after treatment with Tagrisso.
Read moreAstraZeneca enters into exclusive license agreement with CSPC
7th Oct 2024 10:16
(Sharecast News) - Drugmaker AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical to advance the development of a pre-clinical novel lipid-lowering therapy.
Read moreAstraZeneca's Tagrisso gets new US lung cancer approval
26th Sep 2024 07:38
(Sharecast News) - AstraZeneca announced on Thursday that 'Tagrisso', or osimertinib, has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, stage three epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease had not progressed after platinum-based chemoradiation therapy (CRT).
Read moreLondon close: Stocks finish higher after slew of PMI data
23rd Sep 2024 15:05
(Sharecast News) - London's stock markets ended Monday on a positive note, as investors pored over a number of economic activity reports from both the UK and international markets.
Read moreAstraZeneca breast cancer drug trial fails to improve overall survival
23rd Sep 2024 07:17
(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival.
Read moreAstraZeneca's inflammatory disease drug Fasenra approved in the US
18th Sep 2024 07:29
(Sharecast News) - AstraZeneca has received the green light for its Fasenra drug in the US, used to treat patients with a rare inflammatory disease.
Read more